FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer
- PMID: 16702929
FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer
Abstract
Purpose: A number of studies have demonstrated that 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is effective for staging of lung cancer. However, the efficacy of FDG-PET for staging lung cancer after neoadjuvant treatment is still controversial. This study compared FDG-PET and computed tomography (CT) for lung cancer staging, and evaluated the ability of the two methods to predict the pathologic response of the primary tumor to neoadjuvant treatment.
Patients and methods: Twenty-two patients who underwent neoadjuvant treatment followed by surgery were investigated. Eighteen patients received chemoradiotherapy and four patients received chemotherapy only. One hundred and three lymph node stations in the 22 patients were evaluated by FDG-PET and CT. The pathologic responses of the tumors were compared by FDG-uptake and tumor size on CT for the 15 patients who underwent FDG-PET and CT both before and after neoadjuvant treatment.
Results: There was no significant difference in the ability of FDG-PET or CT to predict residual viable tumor. Although positive predictive value by FDG-PET (0.29) was lower than that by CT (0.64) (p=0.04) in the mediastinal lymph nodes, there were no statistically significant differences in the other results of lymph nodes by FDG-PET and CT. Both decrease in FDG-uptake and decrease in tumor size by CT after neoadjuvant treatment correlated significantly with pathologic response in the 15 patients (p=0.003 and 0.009, respectively).
Conclusion: FDG-PET did not appear to offer any advantages over CT for lymph node staging or for predicting the pathologic response after neoadjuvant treatment of non-small cell lung cancer.
Similar articles
-
Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.Eur J Cardiothorac Surg. 2009 Sep;36(3):440-5. doi: 10.1016/j.ejcts.2009.04.003. Epub 2009 May 22. Eur J Cardiothorac Surg. 2009. PMID: 19464906 Review.
-
Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study.J Thorac Cardiovasc Surg. 2006 Jun;131(6):1229-35. doi: 10.1016/j.jtcvs.2005.08.070. J Thorac Cardiovasc Surg. 2006. PMID: 16733150 Clinical Trial.
-
Accuracy of 18F-FDG PET/CT for lymph node staging in non-small-cell lung cancers.Chin Med J (Engl). 2009 Aug 5;122(15):1749-54. Chin Med J (Engl). 2009. PMID: 19781319
-
The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer.Ann Thorac Surg. 2004 Sep;78(3):1017-23; discussion 1017-23. doi: 10.1016/j.athoracsur.2004.02.067. Ann Thorac Surg. 2004. PMID: 15337041 Clinical Trial.
-
CT and PET imaging in non-small cell lung cancer.Crit Rev Oncol Hematol. 2006 Apr;58(1):15-30. doi: 10.1016/j.critrevonc.2005.09.001. Epub 2005 Dec 28. Crit Rev Oncol Hematol. 2006. PMID: 16386435 Review.
Cited by
-
Positron emission tomography in lung cancer.Gen Thorac Cardiovasc Surg. 2009 Apr;57(4):184-91. doi: 10.1007/s11748-008-0371-3. Epub 2009 Apr 15. Gen Thorac Cardiovasc Surg. 2009. PMID: 19367450 Review.
-
Direct nodal sampling by echoendoscopy in lung cancer: the clinician's expectations: Direct nodal sampling by echoendoscopy in lung cancer.Insights Imaging. 2011 Apr;2(2):133-140. doi: 10.1007/s13244-010-0058-z. Epub 2011 Jan 15. Insights Imaging. 2011. PMID: 22347942 Free PMC article.